** Shares of drugmaker BioMarin Pharmaceutical BMRN.O rise 10.5% to $72.51 premarket
** Co, after market close on Wednesday, reported Q4 rev. of $747 mln, beating estimate of $713.4 mln, as per data compiled by LSEG
** Reported Q4 adj. profit of 92 cents per share vs estimate of 53 cents per share
** Forecast 2025 adj. profit in the range of $4.20 to $4.40 per share, above estimate of $3.26 per share
** Brokerage Evercore ISI says BMRN's Q4 results are "solid"; adds "it looks like investors may be willing to reward the company for solid execution after all. This was indeed an encouraging update on multiple fronts"
** Stock had fallen 31.8% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。